Skip to content
  • TearSolutions, Inc.
  • Phase 2 Clinical Trial
  • Mission
  • Team
  • Questions

TearSolutions, Inc.

Natural therapy for dry eye

Questions

Please Email crolph@tearsolutions.com.

Check out us out on Facebook

TearSolutions on LinkedIn

TearSolutions, Inc is a Charlottesville, Virginia drug development company incorporated in Delaware

Share this:

  • Click to print (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)

sidebar

News

  • TearSolutions completes enrollment and screening of Phase 2 trial of Lacripep in Primary Sjogren’s Syndrome dry eye. Results expected in Spring 2020
  • TearSolutions, Inc. Closes $6.4m Financing
  • Middleland Capital’s VTC Innovation Fund and Pharmstandard International Co-lead $8.5m Series B Financing of TearSolutions, Inc. 
  • University of Virginia Licensing & Ventures Group Seed Fund Announces Three Investments

Menu

  • Phase 2 Clinical Trial
  • Mission
  • Team
  • Questions

footer

About This Site

TearSolutions, Inc is a Charlottesville, Virginia drug development company incorporated in Delaware.

 

Find Us

TearSolutions, Inc.
315 Old Ivy Way, Suite 301
Charlottesville, Virginia 22903

Contact TearSolutions CFO Colin Rolph: crolph@tearsolutions.com; 434-951-0444

 

  • Facebook
  • LinkedIn
Proudly powered by WordPress | Theme: Aaron by Carolina